A TRAIL-TL1A Paracrine Network Involving Adipocytes, Macrophages, and Lymphocytes Induces Adipose Tissue Dysfunction

Nitzan Maixner1,2,3, Tal Pecht4,2, Yulia Haim4,2

  • 1Department of Clinical Biochemistry and Pharmacology, Faculty of Health Science, Ben-Gurion University of the Negev, Beer-Sheva, Israel nitzanm7@gmail.com rudich@bgu.ac.il.

Diabetes
|August 1, 2020
PubMed

Insights

Elevated E2F1 in visceral adipose tissue links to poor cardiometabolic health. A novel E2F1-driven pathway involves Tumor Necrosis Factor Superfamily members, impacting immune cells and adipocytes, worsening obesity-related metabolic dysfunction.

Area of Science:

  • Metabolic Research
  • Immunology
  • Obesity Research

Background:

  • Elevated E2F1 in human visceral adipose tissue (hVAT) correlates with adverse cardiometabolic profiles.
  • E2F1's role in obesity-related adipose tissue dysfunction is not fully understood beyond direct signaling pathways.

Purpose of the Study:

  • To investigate the distinct transcriptome governed by E2F1 in hVAT.
  • To elucidate E2F1's contribution to adipose tissue and metabolic dysfunction in obesity.

Main Methods:

  • RNA sequencing of hVAT from obese patients with high (E2F1high) versus low (E2F1low) E2F1 expression.
  • Analysis of Tumor Necrosis Factor Superfamily (TNFSF) member expression and function in adipocytes, T cells, and macrophages.
  • Validation in two independent human cohorts.

Main Results:

  • TNFSF members, including TRAIL and TL1A, were enriched in E2F1high hVAT.
  • TL1A, primarily expressed in SVF T cells, induced by TRAIL, impaired adipocyte lipolysis and altered adipokine secretion.
  • TL1A promoted macrophage foam cell formation and M1 polarization.
  • TL1A and TRAIL expression in hVAT associated with higher leptin, IL6, diabetes, and macrophage lipid content.

Conclusions:

  • A novel intra-adipose E2F1-associated TNFSF paracrine loop involves lymphocytes, macrophages, and adipocytes.
  • This loop contributes significantly to adipose tissue dysfunction in obesity.
  • Targeting this pathway may offer therapeutic strategies for obesity-related metabolic disorders.